Gyre Therapeutics (GYRE) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 21.16% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 45.09% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 80.69% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -4.45% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 8.92% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -117.39% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -117.39% |
| Mar 31, 2026 | -29.64% |
| Dec 31, 2025 | -28.79% |
| Sep 30, 2025 | 57.08% |
| Jun 30, 2025 | 14.04% |
| Mar 31, 2025 | 72.49% |
| Dec 31, 2024 | 46.59% |
| Sep 30, 2024 | 26.97% |
| Jun 30, 2024 | 29.84% |
| Mar 31, 2024 | 28.24% |
| Dec 31, 2023 | 26.97% |
| Sep 30, 2023 | 34.35% |
| Jun 30, 2023 | 28.78% |
| Mar 31, 2023 | 56.11% |
| Dec 31, 2022 | 93.36% |
| Sep 30, 2022 | 7.18% |
| Jun 30, 2022 | -2.21% |
| Mar 31, 2022 | 6.98% |
| Dec 31, 2021 | -24.38% |
| Sep 30, 2021 | -46.53% |